IBRX
ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) has 6 SEC Form 4 filings (15 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 7, 2026.
The most active filer is Director Selecky Christobel with 3 filings. Insiders have net sold $3.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Richard Gerald Adcock
- Employees:671
- HQ:San Diego, CA, US
- IPO:2015-07-28
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.9M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$7.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Cohen CherylFirst filing | Director | Sale | 131,210 | $1.2M | Jul 7 | SEC ↗ |
| Director | Sale | 159,478 | $1.4M | Jul 7 | SEC ↗ | |
Selecky ChristobelFirst filing | Director | Sale | 95,722 | $862K | Jul 1 | SEC ↗ |
Selecky ChristobelFirst filing | Director | Sale | 1,000 | $9K | Jul 1 | SEC ↗ |
| Director | Sale | 25,000 | $197K | Jun 27 | SEC ↗ | |
Simon Barry J.First filing | Director | Sale | 23,033 | $165K | Jun 5 | SEC ↗ |
Related companies
ImmunityBio, Inc. is in the Healthcare sector.